يحاول ذهب - حر

Maharashtra, powerhouse of Indian pharma industry

September 18, 2025

|

Chronicle Pharmabiz

MAHARASHTRA, particularly the Mumbai-Pune corridor, is indisputably the powerhouse of the Indian pharmaceutical industry.

- Namdeo Shinde

Contributing approximately 25-30 per cent of India's total pharmaceutical output and housing over 40 per cent of the nation's pharmaceutical R&D centres, the state is a critical hub for manufacturing, innovation, and exports. However, this preeminent position is challenged by intense domestic competition, infrastructural bottlenecks, environmental concerns, and a rapidly evolving global regulatory landscape.

Region-wise distribution of pharma industry

The pharmaceutical industry in Maharashtra is strategically concentrated in key regional clusters, each with a distinct role. The Mumbai Metropolitan Region (MMR), encompassing Mumbai, Thane, Navi Mumbai, and Palghar, remains the historical and corporate heartland.

It hosts the headquarters of industry giants like Cipla, Sun Pharma, and multinational corporations such as Pfizer and GSK, serving as a central hub for corporate functions, regulatory affairs, marketing, and R&D. While still a dominant centre for formulating complex drugs and vaccines, its high operational costs and space constraints are gradually shifting manufacturing focus to other regions.

According to the Maharashtra Industrial Development Corporation (MIDC), the Mumbai and Konkan region continues to account for a significant, though dynamically changing, portion of the state's pharmaceutical units.

In contrast, Pune has solidified its status as the emerging "Pharma & Biotech Capital" of India. The region, including Pune city, Pimpri-Chinchwad, and Hinjawadi, is an epicentre of innovation, hosting a dense cluster of R&D centres, CRAMS players, and biotech startups, bolstered by world-class institutions like the National Chemical Laboratory and the Serum Institute of India. A report by the India Brand Equity Foundation (IBEF) highlights its prominence, noting over 800 manufacturing units in the broader region.

المزيد من القصص من Chronicle Pharmabiz

Chronicle Pharmabiz

Biocon gets US FDA nod for Bosaya & Aukelso

BIOCON Biologics, a fully integrated global biosimilars company and subsidiary of Biocon has received the US Food and Drug Administration (FDA) approval for Bosaya (denosumab-kyqq) 60 mg/mL injection for subcutaneous use in a single dose prefilled syringe (PFS), and Aukelso (denosumab-kyqq) 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial, biosimilars of Prolia and Xgeva respectively.

time to read

1 mins

September 25, 2025

Chronicle Pharmabiz

Centre to appoint 49 drug inspectors in CDSCO

THE Union Ministry of Health and Family Welfare has notified recruitment of 49 drug inspectors under the Central Drugs Standard Control Organisation (CDSCO), as part of strengthening the organisation's operations to regulate and monitor the drugs and pharmaceutical industry and market in the country.

time to read

1 min

September 25, 2025

Chronicle Pharmabiz

Cold Chain Community to hold conference in Ahmedabad

IN order to create new opportunities in the pharmaceutical cold chain sector, Cold Chain Community, a knowledge-based business platform powered by the National Accreditation Body for Cold Chain Management (NAB-CCM), will hold one-day conference on November 4, 2025 in Ahmedabad.

time to read

1 mins

September 25, 2025

Chronicle Pharmabiz

HC appoints team to conduct inspection on Palamur Bio's facility

THE Delhi High Court (HC) has appointed a three-member inspection team to conduct fresh inspection at the facility of Telan-gana-based preclinical contract research organisation Palamur Biosciences in connection with the allegations raised by the People for the Ethical Treatment of Animals India (PETA India) pertaining to abuse and neglect of animals while carrying out experimentation.

time to read

2 mins

September 25, 2025

Chronicle Pharmabiz

Merck gets 2 positive opinions from CHMP for Keytruda

MERCK, known as MSD outside of the US and Canada, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for Keytruda (pembrolizumab), Merck's anti-PD-1 therapy. One recommends approval of a new subcutaneous (SC) route of administration and a new pharmaceutical form (solution for injection) for Keytruda (pembrolizumab), which if approved would be marketed in the European Union (EU) as Keytruda SC.

time to read

1 min

September 25, 2025

Chronicle Pharmabiz

Aptar's Enbumyst receives US FDA nod

APTAR Pharma, a global leader in drug delivery and active material science solutions and services, announced that its unidose liquid system is the delivery system for the recent US FDA-approved Enbumyst (Bumetanide nasal spray) 0.5mg by Corstasis Therapeutics.

time to read

1 min

September 25, 2025

Chronicle Pharmabiz

Health insurance faces headwinds of escalating medical inflation

HEALTH insurance industry is entering a period of financial stress, driven by two critical factors.

time to read

2 mins

September 25, 2025

Chronicle Pharmabiz

NABL, Ladakh Univ team up to enhance lab capabilities

THE National Accreditation Board for Testing and Calibration Laboratories (NABL) and the University of Ladakh have partnered to enhance testing laboratory capabilities, research, and skill development in Ladakh.

time to read

1 min

September 25, 2025

Chronicle Pharmabiz

AICDF blows whistle on drug cos in U'khand

IN a bold move that could shake the pharmaceutical sector, the All India Chemists and Distributors Federation (AICDF) has submitted a scathing complaint to the National Pharmaceutical Pricing Authority (NPPA), raising serious concerns over the activities of certain drug manufacturers operating out of Uttarakhand.

time to read

2 mins

September 25, 2025

Chronicle Pharmabiz

HC appoints team to conduct inspection on Palamur Bio's facility

THE Delhi High Court (HC) has appointed a three-member inspection team to conduct fresh inspection at the facility of Telangana-based preclinical contract research organisation Palamur Biosciences in connection with the allegations raised by the People for the Ethical Treatment of Animals India (PETA India) pertaining to abuse and neglect of animals while carrying out experimentation.

time to read

2 mins

September 25, 2025

Listen

Translate

Share

-
+

Change font size